Defending Troy
This article was originally published in The Gray Sheet
Executive Summary
Senate Health Committee Chair Judd Gregg (R-N.H.) and House Energy & Commerce Committee Chair Joe Barton (R-Texas) defend FDA Chief Counsel Dan Troy July 22 for filing amicus curiae briefs in product liability cases. In separate floor statements, the congressmen criticized a proposal by Rep. Maurice Hinchey (D-N.Y.) to cut $500,000 from Troy's budget (1"The Gray Sheet" July 26, 2004, p. 7). Barton called Troy's actions "neither unprecedented nor unusual" and observed that two of five former FDA chief counsels who have come to Troy's defense are Democrats...
You may also be interested in...
PMA Approval Preempts State Tort Claims Against Manufacturer – 3rd Circuit
The U.S. Third Circuit appellate court's ruling in Horn v. Thoratec lends weight to recent FDA amicus curiae briefs, which argue agency premarket review of devices preempts state tort claims
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.